Outrun Therapeutics

Proprietary E3 ligase platform to enable protein stabilisation "at source", thereby restoring the body's sophisticated natural disease suppression processes Platform scales the assessment of E3 ligase targets while addressing the historic challenges of drugging these targetsPipeline of first-in-class, small molecule, E3 ligase inhibitors to stabilise proteins and treat disease in several therapeutic areas, including cancer and neurologyLead programme focused on hard-to-treat solid tumoursOriginates from the lab of Prof Satpal Virdee at the MRC Protein Phosphorylation and Ubiquitylation Unit at the University of DundeeView original content:https://www.prnewswire.co.uk/news-releases/outrun-therapeutics-launches-with-a-10m-seed-financing-from-m-ventures-and-mp-healthcare-venture-management-to-develop-a-protein-stabilisation-pipeline-302119662.html